TAG: ADC News

pre-IPO PHARMA

COMPANIES VC JOBS NEWS CONTACT

TAG: ADC

Sep 27, 2023

Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors

Aug 29, 2023

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC

Jul 17, 2023

Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors

Jul 17, 2023

GeneQuantum and InxMed have reached a technology licensing collaboration, providing strong support for innovative ADC drug research and development

May 18, 2023

Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers

May 5, 2023

Araris Biotech AG Supported with CHF 2.5M Swiss Accelerator Grant from Innosuisse to Develop Antibody-Drug Conjugate Candidates

Apr 12, 2023

Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Annual Meeting

Apr 11, 2023

Virtuoso Therapeutics to Present Preclinical Findings on Three Best-in-Class Bispecific and ADC Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Jan 9, 2023

AmMax Bio Enters into an Exclusive Option Agreement with Evopoint Biosciences to License a Next Generation Antibody Drug Conjugate (ADC) for the Treatment of Solid Tumors

Jan 4, 2023

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

Jan 3, 2023

ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Letter for PRO1160, a CD70-Directed ADC

Nov 7, 2022

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate

Oct 18, 2022

Synaffix Licenses CliCr Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

Sep 28, 2022

Brandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics

Sep 7, 2022

Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory Board

Sep 6, 2022

Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal

Aug 31, 2022

Araris Biotech AG to Present at 13th Annual World ADC San Diego 2022

Aug 3, 2022

ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer

Jul 12, 2022

LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate

Jun 2, 2022

ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic

Apr 11, 2022

Adcendo presents Data on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting

Apr 8, 2022

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Apr 6, 2022

BiOneCure Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for BIO-106, a Novel TROP2 ADC for the Treatment of Advanced Solid Tumors

Mar 29, 2022

Araris Biotech AG to Present at 12th Annual World ADC London 2022

Mar 28, 2022

Navrogen Presents Preclinical Data on Its NAV-001 Antibody-Drug Conjugate Program at the 12th World ADC Conference in London

Mar 17, 2022

Mar 17, 2022

Shasqi to Present on SQ3370 and CAPAC Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 17, 2022

Shasqi to Present on SQ3370 and CAPAC™ Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 15, 2022

Mablink Bioscience Announces Appointment of Its Head of Preclinical Research and Development

Mar 1, 2022

Mablink Bioscience announces appointment of its Chief Development Officer

Jan 6, 2022

Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor

Jan 4, 2022

Genmab and Synaffix Enter into License Agreement for ADC Technology

Jan 2, 2022

CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration

Dec 13, 2021

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

Dec 1, 2021

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Oct 21, 2021

Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy

Oct 12, 2021

Araris Biotech AG to Present at 12th Annual World ADC Digital Conference

Aug 9, 2021

Navrogen Closes $3.0M Seed Financing To Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers And Immune-Related Disorders

Aug 4, 2021

Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline

Jul 21, 2021

Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors

Jul 12, 2021

ProfoundBio Announces Completion of More Than $55 million Series A Financing to Advance Novel Antibody-Drug Conjugate (ADC) Portfolio

Jul 7, 2021

Adcendo Appoints Michael Pehl as Chief Executive Officer

Jun 29, 2021

Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent’s Pipeline

Jun 28, 2021

Innovent Announces License Agreement with Synaffix in an ADC Technology Deal

Apr 27, 2021

Pyxis Oncology Presents Preclinical Data and Details on Antibody-Drug Conjugate Candidates Supporting Therapeutic Potential

Apr 27, 2021

Mablink Bioscience, the next generation ADC company, raises €4 Million to move forward its ADC pipeline targeted at cancers with high unmet medical needs

Mar 18, 2021

Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates

Feb 1, 2021

Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles

Dec 2, 2020

Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

Oct 26, 2020

NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors

Oct 9, 2020

Dr. Jutta Wanner Joins Her Next Generation ADC Technology at OS Therapies as Chief Technology Officer

Sep 22, 2020

Synaffix Wins Best Platform Technology at 7th Annual World ADC Awards

Sep 15, 2020

Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors

Aug 3, 2020

NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer

Jul 23, 2020

Synaffix Announces Expansion of Collaboration with ADC Therapeutics

Jul 7, 2020

Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical's ASP-1929 antibody-drug conjugate

May 28, 2020

ADC Therapeutics nomme Victor Sandor, M.D., au sein de son conseil d'administration

May 27, 2020

ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of Directors

May 21, 2020

ADC Therapeutics Appoints Jennifer Creel as Chief Financial Officer

May 21, 2020

ADC Therapeutics nomme Jennifer Creel au poste de directrice financière

May 20, 2020

4BIO Capital portfolio company ADC Therapeutics SA closes an upsized IPO of over $267.6 million

May 14, 2020

ADC Therapeutics Announces Pricing of Upsized Initial Public Offering

May 1, 2020

ADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield

Apr 2, 2020

Bolt Biotherapeutics Appoints Nathan Ihle, Ph.D., as Vice President of CMC and Quality

Mar 19, 2020

ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company

Feb 18, 2020

Global ADC Linker and Conjugation Technologies Markets to 2030 - Featuring Executive Insights from Stakeholders in Miracogen, NBE Therapeutics, Synaffix and EUCODIS Bioscience

Jan 10, 2020

ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs

Jan 10, 2020

ADC Therapeutics désigne Joseph Camardo, MD, au poste de Directeur des affaires médicales

Jan 9, 2020

ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jan 9, 2020

ADC Therapeutics annonce des résultats positifs du test clinique pivot de phase 2 du loncastuximab tesirine (ADCT-402) en monothérapie chez des patients atteints d'un lymphome à grandes cellules B diffuses en rechute ou réfractaire

Jan 7, 2020

Synaffix announces expansion of license agreement with Shanghai Miracogen Inc. to a second ADC candidate

Dec 12, 2019

Zhejiang Medicine and Ambrx Present Positive Top Line Data from a Phase 1a/1b Clinical Trial of ARX788 in Metastatic HER2 Positive Breast Cancer

Dec 10, 2019

ADC Therapeutics annonce la présentation orale des données d'efficacité intermédiaires de l'essai clinique pivot de phase 2 de l'ADCT-402 (loncastuximab tesirine) chez des patients atteints de lymphomes diffus en rechute ou réfractaires à grandes cellules B lors de la 61e réunion annuelle de l'ASH

Dec 10, 2019

ADC Therapeutics kündigt Vortrag über Interimsdaten zur Wirksamkeit aus der Phase-II-Zulassungsstudie zu ADCT-402 (Loncastuximab-Tesirin) bei Patienten mit rezidiviertem oder refraktärem diffusem großzelligem B-Zell-Lymphom auf der 61. Jahrestagung der ASH an

Dec 9, 2019

ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting

Nov 7, 2019

ADC Therapeutics annonce des présentations lors du 61e congrès annuel de l'American Society of Hematology (ASH)

Nov 6, 2019

ADC Therapeutics Announces Presentations at 61st American Society of Hematology (ASH) Annual Meeting

Nov 5, 2019

ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer

Nov 4, 2019

ADC Therapeutics Announces Publication of ADCT-402 Data in Clinical Cancer Research

Oct 17, 2019

ADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma

Oct 17, 2019

ADC Therapeutics dosiert erste Patienten in der klinischen Phase-2-Studie von ADCT-301 bei Patienten mit rezidiviertem oder refraktärem Hodgkin-Lymphom

Oct 17, 2019

ADC Therapeutics administre aux premiers patients de l'essai clinique intermédiaire de phase 2 de l'ADCT-301 chez les patients atteints d'un lymphome de Hodgkin récidivant ou réfractaire

Oct 10, 2019

Forbius: Phase 2 Clinical Data with Tumor-Selective Anti-EGFR ADC AVID100 Featured at AACR-NCI-EORTC and World ADC San Diego

Oct 2, 2019

ADC Therapeutics Announces Withdrawal of Registration Statement

Sep 24, 2019

ADC Therapeutics annonce son introduction en bourse

Sep 23, 2019

ADC Therapeutics Announces Launch of Initial Public Offering

Sep 7, 2019

ADC Therapeutics dépose une demande d'enregistrement pour la première introduction en Bourse proposée

Sep 7, 2019

ADC Therapeutics reicht Registrierungserklärung für den geplanten Börsengang ein

Sep 6, 2019

ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering

Aug 26, 2019

ADC Therapeutics and Freenome Enter Biomarker Development Collaboration

Aug 26, 2019

ADC Therapeutics und Freenome gehen Kooperation zur Entwicklung von Biomarkern ein

Aug 26, 2019

ADC Therapeutics et Freenome concluent une entente de collaboration pour le développement de biomarqueurs

Aug 6, 2019

ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial

Aug 6, 2019

ADC Therapeutics et SOPHiA GENETICS s'associent dans un essai clinique pivot de phase II relatif à une découverte de biomarqueurs

Aug 6, 2019

ADC Therapeutics und SOPHiA GENETICS sind jetzt Partner für die Biomarker-Entdeckung in der klinischen Phase-II-Studie

Jul 23, 2019

Abzena Announces Successful Technical Transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) Technology to Enable Use in Client Projects

Jul 9, 2019

ADC Therapeutics Announces Final Close of Series E Financing Expansion

Jun 21, 2019

ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma

Jun 21, 2019

ADC Therapeutics présente les données cliniques des produits ADCT-402 et ADCT-301 dans les sous-types de lymphomes récidivants ou réfractaires lors la 15e Conférence internationale sur le lymphome malin

Jun 21, 2019

ADC Therapeutics präsentiert auf der 15. Internationalen Konferenz über malignes Lymphom klinische Daten zu ADCT-402 und ADCT-301 in Subtypen von rezidiviertem oder refraktärem Lymphom

Jun 12, 2019

ADC Therapeutics Announces Completion of a Series E Financing Expansion

Jun 12, 2019

ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma

Jun 12, 2019

ADC Therapeutics annonce des présentations lors de la 15e Conférence internationale sur le lymphome malin.

Jun 12, 2019

ADC Therapeutics annonce la réalisation d'une extension du tour de financement de série E

May 28, 2019

ADC Therapeutics Expands to Third Program Using Synaffix’s ADC Platform Under Existing Agreement

May 24, 2019

ADC Therapeutics und Adagene kündigen Lizenzvertrag an

May 16, 2019

Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program

May 14, 2019

Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics

Apr 24, 2019

ADC Therapeutics and Adagene Announce License Agreement

Apr 24, 2019

ADC Therapeutics et Adagene annoncent un accord de licence

Apr 22, 2019

Forbius Announces First Patient Dosed in Phase 2a EGFR-Overexpressing Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC

Apr 10, 2019

Synaffix Announces License Agreement Worth up to $125 Million with Leading Chinese ADC Developer, Shanghai Miracogen

Apr 10, 2019

WuXi Biologics y NBE-Therapeutics anuncian una colaboración completa para el desarrollo y la producción de ADC USA - español USA - English USA - Français USA - Deutsch

Apr 8, 2019

WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership

Apr 8, 2019

WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership USA - English USA - Français USA - Deutsch USA - español

Mar 7, 2019

Forbius Announces First Patient Dosed in Phase 2a Squamous Cell Carcinoma of the Head and Neck (SCCHN) Trial of AVID100, a Novel Anti-EGFR ADC

Mar 5, 2019

Bicycle Therapeutics to Present on BT5528, a Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumours, at World ADC 2019

Feb 20, 2019

Erster Patient in klinischer Studie der Phase I von ADC Therapeutics zu ADCT-402 (Loncastuximab Tesirin) und Ibrutinib bei Patienten mit fortgeschrittenem diffusem großzelligem B-Zell-Lymphom oder Mantelzellen-Lymphom behandelt

Feb 20, 2019

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Feb 20, 2019

ADC Therapeutics annonce le premier patient traité dans le cadre d’un essai clinique de Phase I de l’ADCT-402 (loncastuximab tésirine) et de l’Ibrutinib chez des patients atteints de lymphome diffus à grandes cellules B ou de lymphome à cellules du manteau avancés

Feb 13, 2019

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI® (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma

Feb 13, 2019

ADC Therapeutics gibt ersten behandeten Patienten in klinischer Studie der Phase I zu ADCT-402 (Loncastuximab Tesirin) und IMFINZI® (Durvalumab) bei verschiedenen Arten von fortgeschrittenen Non-Hodgkin-Lymphomen bekannt

Feb 13, 2019

ADC Therapeutics annonce le premier patient traité dans le cadre d’un essai clinique de Phase I de l’ADCT-402 (loncastuximab tésirine) et IMFINZI® (durvalumab) dans plusieurs types de lymphomes non hodgkiniens avancés

Jan 16, 2019

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors

Jan 16, 2019

ADC Therapeutics annonce le premier patient traité dans le cadre d’un essai clinique de Phase I de l’ADCT-601 dans les tumeurs solides avancées

Jan 16, 2019

ADC Therapeutics vermeldet Behandlung des ersten Patienten im Rahmen einer klinischen Phase-1-Studie zu ADCT-601, an der Patienten mit fortgeschrittenen soliden Tumoren teilnehmen

Jan 4, 2019

ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors

Jan 4, 2019

Synaffix Announces License Agreement with Mersana Therapeutics for the Use of its GlycoConnect™ Site-Specific ADC Technology

Jan 4, 2019

ADC Therapeutics behandelt den ersten Patienten in klinischer Studie der Phase Ib zu ADCT-301 bei Patienten mit fortgeschrittenen soliden Tumoren

Jan 4, 2019

ADC Therapeutics traite le premier patient dans le cadre d’un essai clinique de Phase Ib de l’ADCT-301 chez des patients atteints de tumeurs solides

Jan 3, 2019

ADC Therapeutics to Appoint Peter Hug, Ph.D., to Board of Directors

Jan 3, 2019

ADC Therapeutics ernennt Dr. Peter Hug zum Mitglied des Vorstands

Jan 3, 2019

ADC Therapeutics nomme Peter Hug, Ph.D. au Conseil d'administration

Dec 5, 2018

ADC Therapeutics Presents Updated Data from Clinical Trials of Novel Antibody Drug Conjugates

Dec 5, 2018

ADC Therapeutics présente des données actualisées issues d'essais cliniques de nouveaux conjugués anticorps-médicament

Dec 5, 2018

ADC Therapeutics legt aktuelle Daten aus klinischen Studien zu neuen Antikörper-Wirkstoff-Konjugaten vor

Nov 27, 2018

ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Nov 27, 2018

ADC Therapeutics annonce les premiers patients traités dans le cadre de l'essai clinique de Phase I/II sur ADCT-602 dans le traitement de la leucémie aigüe lymphoblastique à lymphocytes B en rechute ou réfractaire

Nov 27, 2018

ADC Therapeutics gibt erste behandelte Patienten in klinischer Studie der Phase I/II zu ADCT-602 bei rezidivierter oder refraktärer akuter lymphatischer B-Zell-Leukämie bekannt

Nov 14, 2018

Bicycle Therapeutics Named Best New Drug Developer at 2018 World ADC Awards

Nov 14, 2018

ADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting

Nov 14, 2018

ADC Therapeutics annonce des présentations au 60e Congrès annuel de l’American Society of Hematology (ASH)

Nov 14, 2018

ADC Therapeutics kündigt Präsentationen auf der 60. Jahrestagung der American Society of Hematology (ASH) an

Nov 8, 2018

ADC Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Nov 8, 2018

ADC Therapeutics kündigt Präsentationen auf der 33. Jahrestagung der Society for Immunotherapy of Cancer (SITC) an

Nov 8, 2018

ADC Therapeutics annonce des présentations à la 33e conférence annuelle de la Society for Immunotherapy of Cancer (SITC)

Oct 23, 2018

Amolyt Pharma Announces European Commission Has Granted Orphan Drug Designation to AZP-3601 for the Treatment of Hypoparathyroidism

Oct 22, 2018

Forbius Announces First Patient Dosed in Phase 2 Trial of anti-EGFR ADC AVID100 in EGFR-Overexpressing Squamous NSCLC

Aug 8, 2018

ADC Therapeutics behandelt ersten Patienten mit ADCT-402 in Schlüsselstudie an Patienten mit rezidivem oder refraktärem diffusem großzelligem B-Zellen-Lymphom

Aug 8, 2018

ADC Therapeutics traite le premier patient dans une étude clinique pivot portant sur l’ADCT-402 pour les patients atteints de lymphome diffus à grandes cellules B récurrent ou réfractaire

Aug 7, 2018

ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jul 27, 2018

Siamab Therapeutics Announces Publication in PLOS ONE of Positive Data from Preclinical Studies of its ST1 Antibody Therapeutic in Development for Ovarian Cancer

May 25, 2018

ADC Therapeutics Announces the Termination of its ADCT-502 Program Targeting HER2 Expressing Solid Tumors

May 11, 2018

ADC Therapeutics to Present Two New Investigational Antibody-Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting

May 1, 2018

Siamab Therapeutics Announces Publication of New Data on its ST1 Lead Program in the Journal Oncotarget

Dec 11, 2017

ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301

Dec 11, 2017

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402

Dec 6, 2017

Synaffix Launches toxSYN™, a New Platform of ADC Payloads

Nov 15, 2017

ADC Therapeutics to Present New Clinical Data for ADCT-402 and ADCT-301 at the American Society of Hematology 2017 Annual Meeting

Oct 23, 2017

ADC Therapeutics Announces Closing of $200 Million Private Financing to Fund Two Lead Programs Through Registrational Trials

Oct 12, 2017

Bicycle Therapeutics Recognised with Multiple Biotech Industry Awards

Oct 11, 2017

ADC Therapeutics Triggers Second Target-Specific License to Synaffix ADC Platform under Existing Agreement

Jun 16, 2017

ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma

May 16, 2017

Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States

Mar 30, 2017

Visterra Awarded CARB-X Contract to Advance Development of VIS705

Dec 21, 2016

Triphase Accelerator Announces New Collaboration with Celgene Corporation for TRPH-222, an anti-CD22 Antibody Drug Conjugate

Dec 8, 2016

Key Synaffix Patent Covering Glycan-Conjugated ADC Process Granted in the United States

Oct 11, 2016

Applied BioMath, LLC Unveils the use of Mathematical Modeling in ADC therapeutics at the 7th Annual World ADC Conference

Sep 27, 2016

Fortis Therapeutics Closes $18 Million Series A Financing to Advance New Antibody Drug Conjugate Therapies for the Treatment of Late-Stage Cancers

Aug 17, 2016

Ambrx's Innovative Antibody Drug Conjugate (ADC) US IND Active

Mar 11, 2016

ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-402 in CD-19 Positive B-cell Non-Hodgkin Lymphomas

Feb 9, 2016

ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-301 Trial in Acute Myeloid Leukemia

Dec 5, 2015

ADC Therapeutics Announces Positive Pre-clinical Results for Two of its Novel ADCs at the American Society of Hematology Conference

Dec 4, 2015

ADC Therapeutics Receives FDA Clearance to Begin Clinical Studies for Its Second Novel Antibody Drug Conjugate ADCT-402 against Lymphomas and Leukemia

Sep 28, 2015

ADC Therapeutics Announces Expanded Board with Appointment of Highly Experienced Non-Executive Directors

Sep 2, 2015

ADC Therapeutics Secures $80m Financing to Progress Its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology

Jun 22, 2015

ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer

Jun 9, 2015

Goodwin Biotechnology and Aspyrian Therapeutics Collaborate on the Successful GMP Manufacturing and IND Submission for a Novel Antibody Drug Conjugate (ADC) Platform

May 27, 2015

Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award

Apr 15, 2015

Asana BioSciences to Present Preclinical Data for a Novel Dual Inhibitor of SYK and JAK Family Kinases and a 5T4-Targeted Antibody Drug Conjugate at the AACR Annual Meeting in Philadelphia, April 18-22, 2015

Mar 16, 2015

ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas

Mar 5, 2015

SynAffix BV to Present Latest Advancement in Antibody-Drug Conjugate Technology at the 9th Annual BIO Europe Spring Conference in Paris

Oct 24, 2014

Glythera Unveils ADC Cysteine Linker Technology

Sep 30, 2014

ADC Therapeutics Expands Team

May 18, 2014

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

Nov 5, 2013

ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology

Nov 5, 2013

ADC Therapeutics Licenses Proprietary Antibodies From Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology

Oct 18, 2013

Covington Advises AstraZeneca/ MedImmune on Acquisition of Spirogen and Investment in and Collaboration with ADC Therapeutics

Jun 24, 2013

VivaMab and ADC Therapeutics Announce Antibody Licensing Deal for Novel ADC Candidate to Target Hematologic Cancers

Jun 17, 2013

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody Drug Conjugate Combining HuMax-TAC and PBD Warhead

Jun 17, 2013

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhead

Jun 17, 2013

Ambrx And Zhejiang Medicine Co. Ltd. Form Collaboration To Develop And Commercialize Ambrx's Antibody Drug Conjugate For Breast Cancer

Jun 16, 2013

Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugate for Breast Cancer

Aug 1, 2012

Adimab and Mersana Announce Antibody-Drug Conjugate Alliance

Jul 17, 2012

ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D

Jul 17, 2012

ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of RandD

Jul 6, 2012

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates

Jun 22, 2011

Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences